|
Latest Press release: PEGASUS-TIMI 54 study of BRILINTA® meets primary endpoint in both 60mg and 90mg doses 14 January 2015 MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology 12 January 2015 LYNPARZA™ approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations 19 December 2014 Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer 18 December 2014 AstraZeneca and Amgen to present detailed results from Phase III AMAGINE-1™ study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis 11 December 2014 Our location: |
Copyright © 2015 Novosci. All rights reserved.